United Therapeutics Corporation $UTHR Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.4% in the third quarter, Holdings Channel.com reports. The firm owned 80,957 shares of the biotechnology company’s stock after selling 8,446 shares during the quarter. Gotham Asset Management LLC’s holdings in United Therapeutics were worth $33,938,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in UTHR. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB grew its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics in the 3rd quarter valued at $44,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ray Kurzweil sold 4,910 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.02, for a total value of $2,401,088.20. Following the transaction, the director directly owned 12,670 shares in the company, valued at approximately $6,195,883.40. This represents a 27.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 516 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $534.99, for a total transaction of $276,054.84. Following the transaction, the chief executive officer directly owned 8,414 shares of the company’s stock, valued at $4,501,405.86. The trade was a 5.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 317,430 shares of company stock worth $155,241,990. Insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 0.3%

Shares of NASDAQ:UTHR opened at $534.30 on Tuesday. The company has a market capitalization of $23.42 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.93 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12. The business has a 50-day moving average price of $487.57 and a 200 day moving average price of $463.88.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.19 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Bank of America restated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $548.09.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.